Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.
Cancer Medicine (2018) Vol. 8, Iss. 1, pp. 137-146
Open Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

Targeted therapy for hepatocellular carcinoma
Ao Huang, Xin–Rong Yang, Wen Yuan Chung, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 550
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, et al.
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 181-223
Open Access | Times Cited: 493
Lenvatinib: A Review in Hepatocellular Carcinoma
Zaina T. Al-Salama, Yahiya Y. Syed, Lesley J. Scott
Drugs (2019) Vol. 79, Iss. 6, pp. 665-674
Closed Access | Times Cited: 242
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
Masatoshi Kudo, Kwang–Hyub Han, Sheng-Long Ye, et al.
Liver Cancer (2020) Vol. 9, Iss. 3, pp. 245-260
Open Access | Times Cited: 240
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Cancer Medicine (2019) Vol. 8, Iss. 8, pp. 3719-3728
Open Access | Times Cited: 153
Systemic Treatment Options in Hepatocellular Carcinoma
Lorenza Rimassa, Tiziana Pressiani, Philippe Merle
Liver Cancer (2019) Vol. 8, Iss. 6, pp. 427-446
Open Access | Times Cited: 111
Emerging agents and regimens for hepatocellular carcinoma
Xiao‐Dong Zhu, Hui‐Chuan Sun
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 93
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Kazuomi Ueshima, Sadahisa Ogasawara, Masafumi Ikeda, et al.
Liver Cancer (2020) Vol. 9, Iss. 5, pp. 583-595
Open Access | Times Cited: 92
Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments
Giovanni Marasco, Matteo Serenari, Matteo Renzulli, et al.
Journal of Gastroenterology (2020) Vol. 55, Iss. 10, pp. 927-943
Open Access | Times Cited: 90
Targeting angiogenesis for liver cancer: Past, present, and future
Xiao‐Dong Zhu, Zhao‐You Tang, Hui‐Chuan Sun
Genes & Diseases (2020) Vol. 7, Iss. 3, pp. 328-335
Open Access | Times Cited: 82
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Oncology (2019) Vol. 97, Iss. 5, pp. 277-285
Closed Access | Times Cited: 80
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, et al.
Cancers (2020) Vol. 12, Iss. 7, pp. 1867-1867
Open Access | Times Cited: 71
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
Sadahisa Ogasawara, Yoshihiko Ooka, Norio Itokawa, et al.
Investigational New Drugs (2019) Vol. 38, Iss. 1, pp. 172-180
Closed Access | Times Cited: 69
Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma
Aya Takahashi, Michihisa Moriguchi, Yuya Seko, et al.
Anticancer Research (2019) Vol. 39, Iss. 9, pp. 5149-5156
Open Access | Times Cited: 61
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 1010-1010
Open Access | Times Cited: 55
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
Sakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
PLoS ONE (2020) Vol. 15, Iss. 4, pp. e0231828-e0231828
Open Access | Times Cited: 54
Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
Shigeo Shimose, Takumi Kawaguchi, Masatoshi Tanaka, et al.
Oncology Letters (2020) Vol. 20, Iss. 3, pp. 2257-2265
Open Access | Times Cited: 54
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
Jaekyung Cheon, Hong Jae Chon, Yeonghak Bang, et al.
Liver Cancer (2020) Vol. 9, Iss. 5, pp. 613-624
Open Access | Times Cited: 51
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
Jing‐Houng Wang, Yen‐Yang Chen, Kwong‐Ming Kee, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 343-343
Open Access | Times Cited: 35
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
Hidekatsu Kuroda, Takayoshi Oikawa, Masashi Ninomiya, et al.
Liver Cancer (2022) Vol. 11, Iss. 4, pp. 383-396
Open Access | Times Cited: 33
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
Andrea Casadei‐Gardini, Margherita Rimini, Masatoshi Kudo, et al.
Liver Cancer (2022) Vol. 11, Iss. 6, pp. 527-539
Open Access | Times Cited: 30
Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings
Ryu Sasaki, Masanori Fukushima, Masafumi Haraguchi, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1769-1769
Open Access | Times Cited: 50
<p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>
Katsuaki Ogushi, Makoto Chuma, Haruki Uojima, et al.
Clinical and Experimental Gastroenterology (2020) Vol. Volume 13, pp. 385-396
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top